查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1933856

磁振造影引導聚焦超音波治療系統市場：按機制、產品、最終用戶和適應症分類－全球預測，2026-2032年

Magnetic Resonance Guided Focused Ultrasound Therapy System Market by Mechanism, Offering, End User, Indication - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年磁振導航導引超音波治療系統市值為5.9728億美元，預計2026年將成長至6.8424億美元，複合年成長率為13.88%，到2032年將達到14.8372億美元。

關鍵市場統計數據
基準年 2025 5.9728億美元
預計年份：2026年 6.8424億美元
預測年份 2032 14.8372億美元
複合年成長率 (%) 13.88%

本文簡要概述了磁振造影（MRI）引導超音波（MRgFUS）作為一種整合型治療平台，如何影響臨床路徑、機構準備和轉化研究。

磁振造影引導超音波（MRgFUS）正從一種小眾研究手段轉變為多個臨床專科微創治療策略的基礎。本文將該技術描述為高解析度成像、精準能量傳遞和不斷發展的臨床通訊協定的完美結合，這些技術共同實現了標靶組織消融、神經調控以及新型藥物遞送技術的進步。接下來的說明將MRgFUS定位為一個整合的平台，它不僅是一種設備類別，更連結了診斷影像、手術流程和轉化研究。

臨床檢驗、模組化架構和跨學科合作如何重塑核磁共振導引聚焦超音波的推廣路徑和商業性競爭格局

磁振造影引導聚焦超音波（MRgFUS）領域正經歷著變革性的轉變，這主要得益於臨床檢驗、模組化技術架構以及不斷拓展的治療目標。臨床證據正從個案研究擴展到多中心研究，這些研究檢驗MRgFUS在神經腫瘤、運動障礙和腫瘤適應症的療效和安全性。因此，醫療機構正在重新思考MRgFUS的部署方式。他們不僅將MRgFUS作為獨立的治療手段，更將其視為一種可以整合到手術室、介入放射學工作流程和研究中心的先進技術。

評估供應鏈、採購和商業模式調整對2025年美國對核磁共振導引聚焦超音波治療實施的累積關稅的影響。

2025年關稅的累積影響為磁共振引導聚焦超音波（MRgFUS）價值鏈上的相關人員帶來了複雜的營運和策略考量。進口組件、成像子系統和精密製造投入的關稅將推高系統製造商的成本，並可能對整個分銷管道產生連鎖反應。這些成本壓力迫使製造商重新評估其供應商基礎，加快關鍵組件的在地採購，並重新談判供應契約，以維持毛利率並避免醫療機構價格突然波動。

深度細分分析揭示了終端使用者專業領域、治療機制、產品供應和臨床適應症如何影響產品採納、證據需求和商業化策略。

一個穩健的細分框架揭示了最終用戶、作用機制、產品供應和適應症對臨床應用、產品開發和商業化的細微影響。從最終用戶的觀點來看，門診手術中心細分為癌症中心和診斷影像中心等次專科，優先考慮手術量、患者體驗和可預測的手術時間。同時，公立和私立醫院都致力於整合複雜的診療路徑並獲得機構認證。研究機構分為學術研究機構和藥物研發部門，強調轉化研究和藥物研發合作。此外，神經外科和腫瘤中心等專科診所專注於疑難病例和多學科協作。

美洲、歐洲、中東和非洲以及亞太地區的區域監管差異、基礎設施優先事項和臨床合作模式都會影響科技的採納和商業化策略。

區域趨勢在塑造臨床應用、監管策略和商業性執行方面發揮著至關重要的作用。在美洲，報銷框架、不斷演變的臨床指南以及介入放射學和神經外科中心的成熟度正在限制機構投資者的投資意願。三級轉診中心和綜合癌症計畫的病患需求與能夠為特定適應症提供低成本、高效率治療的門診手術中心的需求趨於一致。這些因素正在影響供應商的市場推廣重點，並促使他們調整服務協議以適應醫院的採購週期。

生態系統分析著重於製造商、創新新參與企業和策略聯盟如何推動技術差異化、服務模式和臨床合作。

主要企業的發展趨勢正日益受到醫療設備製造商、影像合作夥伴、臨床研究機構和專業服務供應商組成的生態系統的影響，而非單一市場領導的影響。成熟的醫療設備製造商擁有監管經驗、全球服務網路和資金管道等優勢，使其能夠擴展複雜的設備並提供一體化的維護合約。同時，創新Start-Ups公司正透過專注的臨床項目、演算法治療方案以及諸如增強血腦障壁調節和微氣泡輔助遞送等新型機制，推動市場差異化。

為產業領導者提供實用策略指南，以加速磁振造影引導聚焦超音波（MRgFUS）技術的應用，建立臨床夥伴關係，並降低商業化和供應鏈執行風險。

產業領導者應採取多管齊下的策略，整合技術開發、臨床證據產生和商業性柔軟性，以加速技術應用並降低投資風險。首先，應優先考慮模組化產品設計和改造方案，以降低醫療系統的初始資金投入門檻，並加快在學術機構和高運作社區醫療中心進行概念驗證部署。此外，還應輔以有針對性的培訓和認證項目，以減少臨床結果的差異性並培養內部倡導者。

本執行摘要清楚地描述了一種混合方法研究方法，該方法結合了主要臨床訪談、次要證據綜合和專家檢驗，以確保得出可靠、可操作的研究結果。

本執行摘要的調查方法融合了初步定性研究、嚴謹的二手研究以及反覆的專家檢驗，以確保其可靠性和實用性。初步數據是透過對神經外科、介入放射科和腫瘤科的臨床負責人，以及負責影像實驗室管理和資本規劃流程的採購和技術運營相關人員進行結構化訪談收集的。這些訪談直接揭示了臨床工作流程、訓練需求和採購決策標準。

一份綜合分析和未來展望報告，重點闡述了製造商、臨床醫生和支付方為實現磁振造影引導聚焦超音波（MRgFUS）的持續普及必須採取的合作行動。

總之，核磁共振導引聚焦超音波治療正處於關鍵的轉折點，臨床創新、商業化策略和營運執行的交匯點將決定其應用的速度和規模。不斷成長的臨床證據、模組化技術的趨勢以及與製藥和影像合作夥伴的策略合作，正在重新定義非侵入性治療和標靶藥物遞送的可能性。醫療機構能否成功應用該技術，取決於相關人員能否將該技術與臨床路徑整合，同時確保一致的培訓、服務的可靠性和療效評估。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 磁振造影引導聚焦超音波治療系統市場（依機制分類）

  • 血腦障壁開放
  • 藥物輸送
    • 封裝藥物載體
    • 微氣泡導遞送
    • 精準投放
  • 組織溶解療法
  • 神經調控
    • 深部腦部刺激
    • 非侵入性神經調控
  • 熱凝固療法

9. 磁振造影導引聚焦超音波治療系統市場（依產品/服務分類）

  • 配件和零件
    • 配件
    • 消耗品
    • 替換零件
  • 服務
    • 諮詢和培訓
    • 安裝和維護
  • 系統
    • 磁振導航系統
    • 超音波引導系統

第10章 磁振造影導引超音波治療系統市場（依最終使用者分類）

  • 門診手術中心
    • 癌症中心
    • 診斷影像中心
  • 醫院
    • 私立醫院
    • 公立醫院
  • 研究所
    • 學術研究機構
    • 藥物研究與開發研究所
  • 專科診所
    • 神經外科中心
    • 腫瘤中心

第11章 磁振造影導引聚焦超音波治療系統市場（依適應症分類）

  • 骨轉移
  • 乳癌
  • 自發性震顫
  • 肝臟腫瘤
  • 神經系統疾病
    • 腦腫瘤
    • 運動障礙
    • 神經病變疼痛
    • 帕金森氏症
  • 胰臟腫瘤
  • 攝護腺癌
  • 子宮肌瘤

12. 磁振造影引導聚焦超音波治療系統市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 磁振造影導引聚焦超音波治療系統市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國磁振造影引導聚焦超音波治療系統市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

15. 美國磁振造影引導聚焦超音波治療系統市場

第16章 中國磁振造影導引聚焦超音波治療系統市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Alpinion Medical Systems Co., Ltd.
  • Canon Medical Systems Corporation
  • Chongqing Haifu Technology Co., Ltd.
  • EDAP TMS SA
  • EDAP-affiliated product lines
  • EpiSonica
  • EyeTechCare
  • FUJIFILM Holdings
  • FUS Instruments
  • General Electric Company
  • Hitachi, Ltd.
  • Insightec Ltd.
  • Koninklijke Philips NV
  • Medtronic plc
  • Mianyang Sonic Electronic
  • Mirabilis Medical
  • Profound Medical
  • Shanghai A&S Science & Technology
  • Shenzhen Wikkon Medical Technology
  • Siemens Healthineers AG
  • SonaCare Medical
  • SuperSonic Imagine
  • Theraclion SA
Product Code: MRR-C36616F69986

The Magnetic Resonance Guided Focused Ultrasound Therapy System Market was valued at USD 597.28 million in 2025 and is projected to grow to USD 684.24 million in 2026, with a CAGR of 13.88%, reaching USD 1,483.72 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 597.28 million
Estimated Year [2026] USD 684.24 million
Forecast Year [2032] USD 1,483.72 million
CAGR (%) 13.88%

A concise orientation to MR-guided focused ultrasound as a convergent therapeutic platform shaping clinical pathways, institutional readiness, and translational research

Magnetic resonance guided focused ultrasound (MRgFUS) is transitioning from a niche investigational modality to a cornerstone of minimally invasive therapeutic strategies across multiple clinical specialties. This introduction frames the technology as a convergence of high-resolution imaging, precise energy delivery, and evolving clinical protocols that together enable targeted tissue ablation, neuromodulation, and facilitation of novel drug delivery techniques. The narrative that follows positions MRgFUS not just as a device category but as an integrative platform that interfaces with imaging, surgical workflows, and translational research.

Over recent years, momentum has been driven by iterative improvements in MR imaging sequences, enhanced patient workflow integration, and growing clinical evidence across indications ranging from benign gynecologic disease to neurologic conditions. Stakeholders across institutional, research, and commercial settings are assessing how MRgFUS can reduce procedural morbidity, shorten recovery times, and enable previously infeasible therapeutic pathways. As adoption accelerates, strategic questions about site of care readiness, training requirements, reimbursement pathways, and supply chain resilience become central to implementation planning.

This introduction sets the context for deeper analysis of market dynamics, technology differentiation, regulatory headwinds, and competitive positioning. It underscores the need for cross-functional alignment among clinicians, imaging teams, hospital administrators, and commercial partners to convert clinical promise into sustainable clinical programs and reproducible patient outcomes.

How clinical validation, modular architectures, and cross-disciplinary partnerships are reshaping adoption pathways and commercial competition in MR-guided focused ultrasound

The MRgFUS landscape is experiencing transformative shifts driven by clinical validation, modular technology architectures, and expanding therapeutic ambitions. Clinical evidence is broadening from isolated case series to multicenter experiences that validate efficacy and safety across neuro-oncology, movement disorders, and oncologic indications. As a result, institutional adoption is being reimagined: centers are evaluating MRgFUS not only for discrete procedures but as a capability that can be integrated into surgical suites, interventional radiology workflows, and research cores.

Technological evolution is also reshaping the competitive environment. Systems are migrating toward more modular offerings that enable retrofit integration and hybrid imaging guidance, while software advances in treatment planning and real-time monitoring increase procedural confidence. Concurrently, translational initiatives such as blood-brain barrier modulation and microbubble-mediated delivery are expanding the potential therapeutic payloads that MRgFUS can support, creating new intersections with pharmaceutical development and oncology research programs.

Operationally, there is a pronounced shift toward decentralized care models and ambulatory procedural settings for appropriate indications. This transition is tempered by the need for robust training programs, service-level agreements, and cross-disciplinary governance to ensure patient safety and reproducible outcomes. Taken together, these shifts indicate a maturing ecosystem where clinical utility, interoperability, and strategic partnerships determine long-term value rather than simple technology possession.

Assessing the supply chain, procurement, and commercial model adjustments prompted by cumulative United States tariff measures affecting MR-guided focused ultrasound in 2025

The cumulative impact of tariff actions in 2025 presents a complex set of operational and strategic considerations for stakeholders in the MRgFUS value chain. Tariffs on imported components, imaging subsystems, and precision manufacturing inputs increase the cost basis for systems manufacturers and can reverberate through distribution channels. These cost pressures frequently prompt manufacturers to reassess supplier footprints, accelerate localization of critical components, and renegotiate supply agreements to preserve gross margins and avoid abrupt price shifts for institutional buyers.

Beyond direct cost implications, tariffs create timing and logistics challenges. Procurement cycles for capital equipment tend to be long, and uncertainty around duties can delay purchases or prompt institutions to favor already-localized vendors. For manufacturers that rely on specialized overseas expertise for assembly or calibration, tariffs can incentivize nearshoring or the establishment of regional service hubs to maintain competitiveness. These adaptive strategies require upfront investment but can yield more resilient supply chains over time.

Regulatory and contracting processes are also affected. Hospitals and ambulatory centers operating under fixed capital budgets may defer acquisitions during periods of tariff volatility, impacting revenue cycles for providers that offer MRgFUS as a service. In response, vendors are increasingly offering flexible commercial models, including consumable revenue streams, managed service agreements, and phased financing structures to mitigate buyer uncertainty. Ultimately, the tariff environment in 2025 acts as an accelerant for supply chain redesign, regional manufacturing strategies, and commercial model innovation, compelling stakeholders to prioritize agility and diversified sourcing.

Deep segmentation insights revealing how end-user specialties, therapeutic mechanisms, product offerings, and clinical indications shape adoption, evidence needs, and commercialization tactics

A robust segmentation framework reveals nuanced implications for clinical adoption, product development, and commercialization across end users, mechanisms, offerings, and indications. When viewing the market through end-user lenses, ambulatory surgical centers emerge with sub-specializations such as cancer centers and imaging centers that prioritize throughput, patient experience, and predictable procedure times, while hospitals, both private and public, focus on integration with complex care pathways and institutional credentialing. Research institutes split between academic research institutions and pharmaceutical R&D labs, emphasizing translational studies and partnerships for drug delivery, and specialty clinics like neurosurgery and oncology centers concentrate on high-acuity cases and multidisciplinary coordination.

Mechanism-based segmentation clarifies development trajectories and clinical partnerships. Platforms enabling blood-brain barrier opening with reversible disruption attract collaborations with neurologists and pharmaceutical developers pursuing targeted CNS delivery. Drug delivery mechanisms, including encapsulated carriers, microbubble-mediated techniques, and targeted delivery platforms, link closely with translational research and clinical trial design. Histotripsy, characterized by cavitation-induced tissue fractionation, and neuromodulation approaches spanning deep brain stimulation analogs and noninvasive techniques, each require distinct regulatory strategies and clinician training. Thermal ablation, delivered through focused ultrasound ablation methods, aligns with surgical and oncologic workflows and tends to be the most familiar entry point for surgical teams.

Offering segmentation differentiates commercial models and lifecycle support requirements. Accessories and parts, encompassing accessories, consumables, and replacement parts, create recurring revenue opportunities and necessitate robust logistics. Services such as consulting and training as well as installation and maintenance are critical to adoption, particularly for institutions implementing complex imaging-guided procedures. Systems themselves bifurcate between MR-guided systems and ultrasound-guided systems; MR-guided platforms further diverge into fully integrated and retrofit systems, while ultrasound-guided offerings distinguish between integrated coils and standalone systems. Each subcategory carries implications for capital planning, staff competencies, and service ecosystems.

Indication-driven segmentation highlights clinical prioritization and evidence generation pathways. Applications range from bone metastases, breast cancer, essential tremor, liver tumors, pancreatic tumors, prostate cancer, and uterine fibroids to a spectrum of neurological disorders. Within neurological disorders, subcategories such as brain tumors, movement disorders, neuropathic pain, and Parkinson's disease require bespoke trial designs, multidisciplinary care pathways, and long-term outcome tracking. Mapping these segments against payer landscapes and institutional capabilities enables targeted commercialization and clinical research strategies that align with patient need and reimbursement viability.

How regional regulatory diversity, infrastructure priorities, and clinical collaboration models across the Americas, EMEA, and Asia-Pacific influence adoption and commercialization strategies

Regional dynamics play a decisive role in shaping clinical adoption, regulatory strategy, and commercial execution. In the Americas, institutional investment appetite is tempered by reimbursement frameworks, clinical guideline evolution, and the maturity of interventional radiology and neurosurgical centers. Patient demand in tertiary referral centers and integrated cancer programs is converging with interest from ambulatory surgical models that can offer lower-cost, high-throughput care for select indications. These forces shape vendor go-to-market priorities and the structuring of service agreements to align with hospital procurement cycles.

Europe, the Middle East, and Africa present a heterogeneous landscape where regulatory alignment across distinct national health systems and centralized procurement in some countries coexist with highly specialized private providers in others. Clinical adoption is often influenced by national guideline endorsements and demonstration projects within academic centers that then catalyze broader uptake. Service and training partnerships are particularly important in this region, as centers seek capacity-building support to translate clinical evidence into routine practice.

Asia-Pacific is characterized by rapid infrastructure investment, an expanding base of advanced imaging centers, and strong government-led initiatives to bolster domestic manufacturing capabilities. Several markets within the region are prioritizing localized production and skills development, which creates potential opportunities for manufacturers prepared to invest in localized support. Across all regions, cross-border collaborations in clinical research and shared registries are emerging as critical mechanisms for accelerating evidence generation and harmonizing best practices.

Competitive ecosystem analysis emphasizing how manufacturers, innovative entrants, and strategic partnerships drive technology differentiation, service models, and clinical collaboration

Key company dynamics are defined less by singular market leaders and more by an ecosystem of device manufacturers, imaging partners, clinical research organizations, and specialized service providers. Established medical device manufacturers bring strengths in regulatory experience, global service networks, and capital access, which enable them to scale complex installations and offer integrated maintenance contracts. At the same time, innovative startups are driving differentiation through focused clinical programs, algorithmic treatment planning, and novel mechanisms such as enhanced blood-brain barrier modulation and microbubble-assisted delivery.

Strategic partnerships are increasingly central to competitive positioning. Collaborations between device vendors and pharmaceutical developers create co-development pathways for indications that marry focused ultrasound delivery with targeted therapeutics. Similarly, alliances with imaging vendors and systems integrators facilitate smoother workflow integration and reduce adoption friction at hospital sites. Service providers that specialize in training and clinical workflow optimization add value by shortening the learning curve for new adopters and improving first-case success rates.

Given the capital intensity of system deployment, companies that offer flexible commercial arrangements-leasing, managed services, or outcome-linked models-can accelerate adoption among budget-constrained institutions. The competitive landscape also rewards firms that invest in robust real-world evidence programs and registries, as longitudinal clinical outcomes will increasingly inform payer decisions and guideline formulation.

Actionable strategic playbook for industry leaders to accelerate adoption, anchor clinical partnerships, and de-risk commercial and supply chain execution in MRgFUS

Industry leaders should adopt a multi-pronged strategy that aligns technology development, clinical evidence generation, and commercial flexibility to accelerate adoption and de-risk investment. First, prioritize modular product architectures and retrofit options that reduce upfront capital barriers for health systems, enabling faster proof-of-concept deployments in academic and high-volume community centers. This approach should be complemented by targeted training and certification programs that reduce variability in clinical outcomes and build institutional champions.

Second, invest in strategic alliances with pharmaceutical developers and translational research centers to co-design trials that demonstrate the unique value proposition of combining focused ultrasound with targeted therapeutic agents. These collaborations can open new reimbursement pathways and create differentiated clinical indications that are difficult for competitors to replicate. Simultaneously, vendors should develop comprehensive service models that include installation, ongoing maintenance, and clinical workflow consultancy to minimize operational friction and maximize uptime.

Third, diversify supply chains and consider regional manufacturing or assembly hubs to mitigate tariff exposure and logistics risk. Building local service capabilities reduces time-to-repair and strengthens relationships with institutional purchasers. Finally, adopt data-driven commercialization strategies: deploy registries, real-world evidence collection, and outcome analytics to demonstrate long-term value and support payer negotiations. By executing these recommendations, industry leaders can create a defensible market position that balances innovation with scalability.

Transparent description of a mixed-methods research approach combining primary clinical interviews, secondary evidence synthesis, and expert validation to ensure robust actionable insights

The research methodology underpinning this executive summary integrates primary qualitative engagement, rigorous secondary analysis, and iterative expert validation to ensure credibility and practical relevance. Primary inputs were gathered through structured interviews with clinical leaders across neurosurgery, interventional radiology, and oncology, as well as procurement and technical operations stakeholders who manage imaging suites and capital planning processes. These conversations provided firsthand insights into clinical workflows, training needs, and procurement decision criteria.

Secondary research reviewed peer-reviewed clinical literature, regulatory filings, device technical specifications, and publicly available clinical guidelines to triangulate clinical efficacy, safety considerations, and regulatory pathways. Market intelligence was synthesized by mapping technology roadmaps, patent activity, and partnerships to identify strategic trends and innovation vectors. Data triangulation and cross-validation steps reconciled divergent perspectives and ensured that conclusions reflected both clinical realities and commercial imperatives.

Finally, findings were subjected to expert panel review, where thought leaders from clinical, regulatory, and commercial domains critiqued assumptions, validated segmentation frameworks, and recommended interpretative adjustments. Quality controls included source provenance tracking, conflict-of-interest assessments for interviewees, and iterative revisions to ensure clarity and actionable relevance for decision-makers seeking to deploy or invest in MRgFUS capabilities.

Synthesis and forward-looking assessment highlighting the coordinated actions required from manufacturers, clinicians, and payers to realize sustained MRgFUS adoption

In conclusion, MR-guided focused ultrasound stands at an inflection point where clinical innovation, commercialization strategy, and operational execution intersect to determine the pace and scale of adoption. Clinical evidence expansion, modular technology trends, and strategic collaborations with pharmaceutical and imaging partners are collectively redefining what is possible for noninvasive therapies and targeted drug delivery. Institutional adoption will hinge on the ability of stakeholders to integrate technology into clinical pathways while ensuring consistent training, service reliability, and outcome measurement.

External forces such as tariff environments, regional regulatory diversity, and capital procurement practices will shape vendor strategies around localization, flexible commercial terms, and service offerings. Companies that proactively address supply chain resilience, invest in real-world evidence, and design scalable training programs will be best positioned to convert clinical promise into routine care. For health systems and research institutions, the imperative is to align clinical priorities with measurable outcome goals and to leverage strategic partnerships that accelerate translational research and patient access.

Overall, the pathway to broad adoption depends on coordinated efforts across manufacturers, clinical champions, service providers, and payers to demonstrate sustained clinical benefit, operational viability, and economic value. Stakeholders who act decisively to address these dimensions will shape the next generation of therapeutic care enabled by MRgFUS.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Magnetic Resonance Guided Focused Ultrasound Therapy System Market, by Mechanism

  • 8.1. Blood Brain Barrier Opening
  • 8.2. Drug Delivery
    • 8.2.1. Encapsulated Drug Carriers
    • 8.2.2. Microbubble Mediated Delivery
    • 8.2.3. Targeted Delivery
  • 8.3. Histotripsy
  • 8.4. Neuromodulation
    • 8.4.1. Deep Brain Stimulation
    • 8.4.2. Non Invasive Neuromodulation
  • 8.5. Thermal Ablation

9. Magnetic Resonance Guided Focused Ultrasound Therapy System Market, by Offering

  • 9.1. Accessories And Parts
    • 9.1.1. Accessories
    • 9.1.2. Consumables
    • 9.1.3. Replacement Parts
  • 9.2. Services
    • 9.2.1. Consulting And Training
    • 9.2.2. Installation And Maintenance
  • 9.3. Systems
    • 9.3.1. MR Guided Systems
    • 9.3.2. Ultrasound Guided Systems

10. Magnetic Resonance Guided Focused Ultrasound Therapy System Market, by End User

  • 10.1. Ambulatory Surgical Centers
    • 10.1.1. Cancer Centers
    • 10.1.2. Imaging Centers
  • 10.2. Hospitals
    • 10.2.1. Private Hospitals
    • 10.2.2. Public Hospitals
  • 10.3. Research Institutes
    • 10.3.1. Academic Research Institutes
    • 10.3.2. Pharmaceutical R&D Labs
  • 10.4. Specialty Clinics
    • 10.4.1. Neurosurgery Centers
    • 10.4.2. Oncology Centers

11. Magnetic Resonance Guided Focused Ultrasound Therapy System Market, by Indication

  • 11.1. Bone Metastases
  • 11.2. Breast Cancer
  • 11.3. Essential Tremor
  • 11.4. Liver Tumors
  • 11.5. Neurological Disorders
    • 11.5.1. Brain Tumors
    • 11.5.2. Movement Disorders
    • 11.5.3. Neuropathic Pain
    • 11.5.4. Parkinsons Disease
  • 11.6. Pancreatic Tumors
  • 11.7. Prostate Cancer
  • 11.8. Uterine Fibroids

12. Magnetic Resonance Guided Focused Ultrasound Therapy System Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Magnetic Resonance Guided Focused Ultrasound Therapy System Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Magnetic Resonance Guided Focused Ultrasound Therapy System Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Magnetic Resonance Guided Focused Ultrasound Therapy System Market

16. China Magnetic Resonance Guided Focused Ultrasound Therapy System Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Alpinion Medical Systems Co., Ltd.
  • 17.6. Canon Medical Systems Corporation
  • 17.7. Chongqing Haifu Technology Co., Ltd.
  • 17.8. EDAP TMS SA
  • 17.9. EDAP-affiliated product lines
  • 17.10. EpiSonica
  • 17.11. EyeTechCare
  • 17.12. FUJIFILM Holdings
  • 17.13. FUS Instruments
  • 17.14. General Electric Company
  • 17.15. Hitachi, Ltd.
  • 17.16. Insightec Ltd.
  • 17.17. Koninklijke Philips N.V.
  • 17.18. Medtronic plc
  • 17.19. Mianyang Sonic Electronic
  • 17.20. Mirabilis Medical
  • 17.21. Profound Medical
  • 17.22. Shanghai A&S Science & Technology
  • 17.23. Shenzhen Wikkon Medical Technology
  • 17.24. Siemens Healthineers AG
  • 17.25. SonaCare Medical
  • 17.26. SuperSonic Imagine
  • 17.27. Theraclion SA

LIST OF FIGURES

  • FIGURE 1. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY MECHANISM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY BLOOD BRAIN BARRIER OPENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY BLOOD BRAIN BARRIER OPENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY BLOOD BRAIN BARRIER OPENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY DRUG DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY DRUG DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY DRUG DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY DRUG DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ENCAPSULATED DRUG CARRIERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ENCAPSULATED DRUG CARRIERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ENCAPSULATED DRUG CARRIERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY MICROBUBBLE MEDIATED DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY MICROBUBBLE MEDIATED DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY MICROBUBBLE MEDIATED DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY TARGETED DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY TARGETED DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY TARGETED DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY HISTOTRIPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY HISTOTRIPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY HISTOTRIPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROMODULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROMODULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROMODULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROMODULATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY DEEP BRAIN STIMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY DEEP BRAIN STIMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY DEEP BRAIN STIMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NON INVASIVE NEUROMODULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NON INVASIVE NEUROMODULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NON INVASIVE NEUROMODULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY THERMAL ABLATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY THERMAL ABLATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY THERMAL ABLATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ACCESSORIES AND PARTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ACCESSORIES AND PARTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ACCESSORIES AND PARTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ACCESSORIES AND PARTS, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ACCESSORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ACCESSORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ACCESSORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY REPLACEMENT PARTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY REPLACEMENT PARTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY REPLACEMENT PARTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY CONSULTING AND TRAINING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY CONSULTING AND TRAINING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY CONSULTING AND TRAINING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY INSTALLATION AND MAINTENANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY INSTALLATION AND MAINTENANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY INSTALLATION AND MAINTENANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY MR GUIDED SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY MR GUIDED SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY MR GUIDED SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ULTRASOUND GUIDED SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ULTRASOUND GUIDED SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ULTRASOUND GUIDED SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY CANCER CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY CANCER CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY CANCER CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY IMAGING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY IMAGING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY IMAGING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY PHARMACEUTICAL R&D LABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY PHARMACEUTICAL R&D LABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY PHARMACEUTICAL R&D LABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROSURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROSURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROSURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ONCOLOGY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ONCOLOGY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ONCOLOGY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY BONE METASTASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY BONE METASTASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY BONE METASTASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ESSENTIAL TREMOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ESSENTIAL TREMOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ESSENTIAL TREMOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY LIVER TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY LIVER TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY LIVER TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY BRAIN TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY BRAIN TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY BRAIN TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY MOVEMENT DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY MOVEMENT DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY MOVEMENT DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROPATHIC PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROPATHIC PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY PARKINSONS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY PARKINSONS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY PARKINSONS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY PANCREATIC TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY PANCREATIC TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY PANCREATIC TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY UTERINE FIBROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY UTERINE FIBROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY UTERINE FIBROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY DRUG DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROMODULATION, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ACCESSORIES AND PARTS, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY DRUG DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROMODULATION, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ACCESSORIES AND PARTS, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY DRUG DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROMODULATION, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ACCESSORIES AND PARTS, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY DRUG DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROMODULATION, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ACCESSORIES AND PARTS, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY DRUG DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROMODULATION, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY ACCESSORIES AND PARTS, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY DRUG DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND THERAPY SYSTEM MARKET SIZE, BY NEUROMODULATION, 2018-2032 (USD MILLION)